Phase II study of docetaxel in patients with relapsed or refractory malignant lymphoma

J. M. Zekri, R. E. Hough, J. M. Davies, R. Molife, B. W. Hancock, P. C. Lorigan

    Research output: Contribution to journalArticlepeer-review

    Abstract

    We report the activity and toxicity of docetaxel in 12 evaluable heavily pretreated patients with relapsed and refractory non-Hodgkin's lymphoma and Hodgkin's disease. In all, 42% achieved a partial response, 25% achieved stable disease. Median duration of response was 16 (10-21) weeks. The median overall survival was 70 (9-178) weeks and for responders it was 120 (22-178) weeks. One patient developed one episode of neutropenic sepsis. Docetaxel has limited activity in this group of patients. © 2003 Cancer Research UK.
    Original languageEnglish
    Pages (from-to)1335-1338
    Number of pages3
    JournalBritish Journal of Cancer
    Volume88
    Issue number9
    DOIs
    Publication statusPublished - 6 May 2003

    Keywords

    • Docetaxel
    • Hodgkin's disease
    • Non-Hodgkin's lymphoma

    Fingerprint

    Dive into the research topics of 'Phase II study of docetaxel in patients with relapsed or refractory malignant lymphoma'. Together they form a unique fingerprint.

    Cite this